OGT's FY2014 Revenues Rise 27 Percent on CytoSure Array, Cytocell FISH Sales, NGS Services | GenomeWeb

NEW YORK (GenomeWeb) – Oxford Gene Technology this week provided an update of its operations and finances for its fiscal year 2014, which ended on Sept. 30.  For the first time ever, the privately held, Oxford, UK-based company reported its total and commercial revenues, a trend that OGT CEO Mike Evans said could continue as the firm raises its profile.

"Over the last 12 months, OGT has made a number of important operational decisions to help achieve our ambition to become a global leader in molecular genetics," Evans told GenomeWeb in an email.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.